[HTML][HTML] CRISPR/Cas therapeutic strategies for autosomal dominant disorders

SM Caruso, PMJ Quinn, BL da Costa… - The Journal of clinical …, 2022 - Am Soc Clin Investig
Autosomal dominant disorders present unique challenges, as therapeutics must often
distinguish between healthy and diseased alleles while maintaining high efficiency …

CRISPR/Cas therapeutic strategies for autosomal dominant disorders

SM Caruso, PMJ Quinn, BL da Costa… - Journal of Clinical …, 2022 - search.proquest.com
Autosomal dominant disorders present unique challenges, as therapeutics must often
distinguish between healthy and diseased alleles while maintaining high efficiency …

[PDF][PDF] CRISPR/Cas therapeutic strategies for autosomal dominant disorders

SM Caruso, PMJ Quinn, BL da Costa, SH Tsang - 2022 - pdfs.semanticscholar.org
Conflict of interest: SHT receives grant support from Abeona Therapeutics Inc. and Emendo.
SHT is also the founder of Rejuvitas and is on the scientific and clinical advisory board for …

CRISPR/Cas therapeutic strategies for autosomal dominant disorders.

SM Caruso, PM Quinn, BL da Costa… - The Journal of Clinical …, 2022 - europepmc.org
Autosomal dominant disorders present unique challenges, as therapeutics must often
distinguish between healthy and diseased alleles while maintaining high efficiency …

[HTML][HTML] CRISPR/Cas therapeutic strategies for autosomal dominant disorders

SM Caruso, PMJ Quinn, BL da Costa… - The Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
Autosomal dominant disorders present unique challenges, as therapeutics must often
distinguish between healthy and diseased alleles while maintaining high efficiency …

CRISPR/Cas therapeutic strategies for autosomal dominant disorders

SM Caruso, PM Quinn… - The Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Autosomal dominant disorders present unique challenges, as therapeutics must often
distinguish between healthy and diseased alleles while maintaining high efficiency …